Bimagrumab (BYM338) is a human monoclonal antibody first developed by Novartis and currently by Eli Lilly to treat pathological muscle loss and weakness. It binds to and inhibits activin receptor type-2B.
The compounds of every Wikipedia article carrying a Chembox or a Drugbox, refreshed daily, with the values their infoboxes give. The pages need JavaScript; the API does not.